Published in Medical Letter on the CDC and FDA, October 26th, 2008
ATryn is under review for the treatment of a rare disorder called hereditary antithrombin deficiency, or HD, involving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.